AGILENT TECHNOLOGIES, INC. A

Technology SIC 3826 - Laboratory Analytical Instruments NAICS Manufacturing › Computer and Electronic Product Manufacturing › Navigational, Measuring, Electromedical, and Control Instruments Manufacturing › Analytical Laboratory Instrument Manufacturing derived NYSE

Agilent Technologies, Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow.

In November 2024, we announced a change in our organizational structure to support our market-focused, customer-centric strategy. Our former Diagnostics and Genomics segment combined with our liquid chromatography and liquid chromatography mass spectrometry instrument platforms to form our new Life Sciences and Diagnostics Markets segment. Our chemistries and supplies, laboratory automation, and software and informatics divisions moved from our former Life Sciences and Applied Markets segment to our Agilent CrossLab segment. The remaining divisions in our former Life Sciences and Applied Markets segment which includes our gas chromatography, gas chromatography mass spectrometry, remarketed instruments, spectroscopy and vacuum divisions formed our new Applied Markets segment.

Last close 173.07 2026-10-23
Market cap $48.79B 2026-07-31 share count
52-week range 108.35 - 179.10

Valuation FY2025 figures against the last close

P/S7.0x
P/E37.9x
P/FCF42.4x
EV/EBITDA28.5x
Dividend yield0.6%
Diluted EPS4.57

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • Americas
  • Asia Pacific
  • Europe
Revenue by geography, 3 categories over 3 years. The same figures are in the table below. FY2025 Americas, FY2025: 2.8B (40.4%) 40% Americas Asia Pacific, FY2025: 2.2B (31.9%) 32% Asia Pacific Europe, FY2025: 1.9B (27.7%) 28% Europe FY2024 Americas, FY2024: 2.6B (39.5%) 40% Asia Pacific, FY2024: 2.2B (33.3%) 33% Europe, FY2024: 1.8B (27.2%) 27% FY2023 Americas, FY2023: 2.7B (40.0%) 40% Asia Pacific, FY2023: 2.3B (34.3%) 34% Europe, FY2023: 1.8B (25.7%) 26%
Region FY2025FY2024FY2023
Americas $2.81B $2.57B $2.73B
Asia Pacific $2.22B $2.17B $2.35B
Europe $1.92B $1.77B $1.75B

As the company reported it, from the “REVENUE - Revenue by Region (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $6.95B$6.51B$6.83B$6.85B$6.32B$5.34B$5.16B$4.91B$4.47B$4.20B
Cost of revenue $3.31B$2.98B$3.37B$3.13B$2.91B$2.50B$2.36B$2.23B$2.07B$2.00B
Gross profit $3.64B$3.54B$3.46B$3.72B$3.41B$2.84B$2.81B$2.68B$2.40B$2.20B
R&D $455.0M$479.0M$481.0M$467.0M$441.0M$495.0M$404.0M$387.0M$341.0M$329.0M
SG&A $1.71B$1.57B$1.63B$1.64B$1.62B$1.50B$1.46B$1.39B$1.25B$1.25B
Total operating expenses $5.47B$5.02B$5.48B$5.23B$4.97B$4.49B$4.22B$4.01B$3.67B$3.59B
Operating income $1.48B$1.49B$1.35B$1.62B$1.35B$846.0M$941.0M$904.0M$807.0M$615.0M
Interest expense $112.0M$96.0M$95.0M$84.0M$81.0M$78.0M$74.0M$75.0M$79.0M$72.0M
Pre-tax income $1.44B$1.52B$1.34B$1.50B$1.36B$842.0M$919.0M$946.0M$803.0M$544.0M
Income tax $132.0M$232.0M$99.0M$250.0M$150.0M$123.0M$152.0M$630.0M$119.0M$82.0M
Net income $1.30B$1.29B$1.24B$1.25B$1.21B$719.0M$1.07B$316.0M$684.0M$462.0M
EPS, basic 4.594.444.224.193.982.333.410.982.121.42
EPS, diluted 4.574.434.194.183.942.303.370.972.101.40
Shares, diluted (wtd. avg.) 285.0M291.0M296.0M300.0M307.0M312.0M318.0M325.0M326.0M329.0M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $1.79B$1.33B$1.59B$1.06B$1.49B$1.45B$1.39B$2.25B$2.69B$2.29B
Receivables $1.49B$1.32B$1.29B$1.41B$1.17B$1.04B$930.0M$776.0M$724.0M$631.0M
Inventory $1.02B$972.0M$1.03B$1.04B$830.0M$720.0M$679.0M$638.0M$575.0M$533.0M
Total current assets $4.59B$3.96B$4.19B$3.78B$3.80B$3.42B$3.19B$3.85B$4.17B$3.63B
Property, plant and equipment $2.02B$1.78B$1.27B$1.10B$945.0M$845.0M$850.0M$822.0M$757.0M$639.0M
Goodwill $4.47B$4.48B$3.96B$3.95B$3.98B$3.60B$3.59B$2.97B$2.61B$2.52B
Other intangibles $445.0M$547.0M$475.0M$821.0M$981.0M$831.0M$1.11B$491.0M$361.0M$416.0M
Total assets $12.73B$11.85B$10.76B$10.53B$10.71B$9.63B$9.45B$8.54B$8.43B$7.79B
Accounts payable $570.0M$540.0M$418.0M$580.0M$446.0M$354.0M$354.0M$340.0M$305.0M$257.0M
Short-term debt $304.0M$45.0M$0$36.0M$0$75.0M$616.0M$0$210.0M$0
Total current liabilities $2.35B$1.90B$1.60B$1.86B$1.71B$1.47B$2.08B$1.17B$1.26B$945.0M
Long-term debt $3.05B$3.35B$2.73B$2.73B$2.73B$2.28B$1.79B$1.80B$1.80B$1.90B
Total liabilities $5.99B$5.95B$4.92B$5.23B$5.32B$4.75B$4.70B$3.97B$3.59B$3.55B
Retained earnings $1.39B$750.0M$782.0M$324.0M$348.0M$81.0M-$18.0M-$336.0M-$126.0M$6.09B
Total equity $6.74B$5.90B-$327.0M$5.30B$5.39B$4.87B$4.75B$4.57B$4.83B$4.25B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $1.56B$1.75B$1.77B$1.31B$1.49B$921.0M$1.02B$1.09B$889.0M$793.0M
Depreciation and amortisation $288.0M$257.0M$271.0M$317.0M$321.0M$308.0M$238.0M$210.0M$212.0M$246.0M
Stock-based compensation $128.0M$129.0M$111.0M$125.0M$110.0M$83.0M$72.0M$70.0M$60.0M$58.0M
Capital expenditure $407.0M$378.0M$298.0M$291.0M$188.0M$119.0M$155.0M$177.0M$176.0M$139.0M
Investing cash flow -$394.0M-$1.26B-$310.0M-$338.0M-$749.0M-$147.0M-$1.59B-$705.0M-$304.0M-$238.0M
Financing cash flow -$715.0M-$752.0M-$930.0M-$1.37B-$696.0M-$717.0M-$299.0M-$797.0M-$202.0M-$268.0M
Dividends paid $282.0M$274.0M$265.0M$250.0M$236.0M$222.0M$206.0M$191.0M$170.0M$150.0M
Buybacks $425.0M$1.15B$575.0M$1.14B$788.0M$469.0M$723.0M$422.0M$194.0M$434.0M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001090872-25-000087.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. 0 2B 4B 6B 8B Revenue, FY2016: 4.2B Gross profit, FY2016: 2.2B Net income, FY2016: 462M Revenue, FY2017: 4.5B Gross profit, FY2017: 2.4B Net income, FY2017: 684M Revenue, FY2018: 4.9B Gross profit, FY2018: 2.7B Net income, FY2018: 316M Revenue, FY2019: 5.2B Gross profit, FY2019: 2.8B Net income, FY2019: 1.1B Revenue, FY2020: 5.3B Gross profit, FY2020: 2.8B Net income, FY2020: 719M Revenue, FY2021: 6.3B Gross profit, FY2021: 3.4B Net income, FY2021: 1.2B Revenue, FY2022: 6.8B Gross profit, FY2022: 3.7B Net income, FY2022: 1.3B Revenue, FY2023: 6.8B Gross profit, FY2023: 3.5B Net income, FY2023: 1.2B Revenue, FY2024: 6.5B Gross profit, FY2024: 3.5B Net income, FY2024: 1.3B Revenue, FY2025: 6.9B Gross profit, FY2025: 3.6B Net income, FY2025: 1.3B FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $4.20B $4.47B $4.91B $5.16B $5.34B $6.32B $6.85B $6.83B $6.51B $6.95B
Gross profit $2.20B $2.40B $2.68B $2.81B $2.84B $3.41B $3.72B $3.46B $3.54B $3.64B
Net income $462.0M $684.0M $316.0M $1.07B $719.0M $1.21B $1.25B $1.24B $1.29B $1.30B

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Results announced Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Officer or director change Item 5.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Officer or director change Item 5.02
  • Change of control Control of the company has changed hands. Item 5.01
  • Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Officer or director change Item 5.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3826

TickerCompanyMarket capP/ERevenue growth
WAT WATERS CORP /DE/ $44.57B 42.2x 7.0%
ILMN ILLUMINA, INC. $40.68B 49.4x -0.7%
MTD METTLER TOLEDO INTERNATIONAL INC/ $33.47B 39.7x 4.0%
RVTY REVVITY, INC. $17.72B 76.7x 3.7%
AVTR Avantor, Inc. $11.80B — -3.4%
BIO BIO-RAD LABORATORIES, INC. $9.89B 13.3x 0.7%
TXG 10x Genomics, Inc. $9.30B — 5.2%
BRKR BRUKER CORP $8.74B — 2.1%